View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 21, 2016updated 13 Jul 2022 10:13am

Targazyme begins patient enrolment in Phase I/II trial of TZ 101 regulatory T-cell to treat GVHD

US-based biopharmaceutical company Targazyme has recruited the first patient in its Phase I/II clinical trial of TZ 101-treated regulatory T-cell (Tregs) to treat and prevent acute and chronic graft-versus-host-disease (GVHD) in stem cell transplants.

US-based biopharmaceutical company Targazyme has recruited the first patient in its Phase I/II clinical trial of TZ 101-treated regulatory T-cell (Tregs) to treat and prevent acute and chronic graft-versus-host-disease (GVHD) in stem cell transplants.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

TZ101 is the company’s clinical-grade fucosyltransferase enzyme and small molecule product, which is available as off-the-shelf biologic products indicated to treat therapeutic cells immediately before administering it to the patient.

The Phase I/II clinical trial has been designed to evaluate the safety and efficacy of an ex-vivo treatment of Tregs addressing GVHD.

Targazyme CEO Lynnet Koh said: "The initiation of the Phase I/II study with TZ 101-treated regulatory T-cells in the stem cell transplant setting is an important clinical milestone for our evaluation of TZ101 as a potential treatment for patients suffering from GVHD and life-threatening autoimmune diseases."

"The Phase I/II clinical trial has been designed to evaluate the safety and efficacy of an ex-vivo treatment of Tregs addressing GVHD."

According to the company, the new trial builds on available clinical data that TZ101 improves time to absolute neutrophil count and platelet recovery in patients undergoing hematopoietic stem cell transplants.

Both TZ101 and the company's second product TZ102 provides proof of concept that these products are enabling technologies for improving efficacy outcomes for various cells such as T cells, natural killer cells, and hematopoietic, cardiac and neural stem cells.

These are used to prevent and treat a variety of different diseases, for which there is a high unmet medical need.

GVHD is characterised by fatal complication of hematopoietic stem cell and solid organ transplantation, which is addressed by the regulatory T-cells and considered a key component of the immune system.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena